Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma
Medical Molecular Morphology · 10.06.2026
DOI: 10.1007/s00795-026-00466-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Molecular Morphology, online erschienen am 10.06.2026. Verfasst von Yoshihiko Kondo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kumamoto University.
Abstract (Originalsprache)
Multiple myeloma (MM) is a malignant plasma cell neoplasm characterized by marked biological heterogeneity and complex metabolic reprogramming. Although dysregulated lipid metabolism has been implicated in MM, its morphological correlations and clinical significance remain unclear. The present study evaluated cytoplasmic vacuoles in peripheral blood smears and analyzed their associations with the prognosis and stage of MM. Additionally, lipid droplet formation and the expression of key cholesterol regulatory molecules among MM cell lines were examined via molecular and biochemical approaches. Intracytoplasmic vacuoles were more frequently observed at advanced Revised International Staging System stages of MM, although no significant difference in overall survival was observed. MM cell lines exhibited prominent lipid droplet accumulation and upregulated acyl-coenzyme A:cholesterol acyltransferase-1 (ACAT-1) and scavenger receptor class B type I (SR-BI) expression. The pharmacological inhibition of SR-BI suppressed MM cell proliferation and induced apoptotic cell death, whereas the inhibition of ACAT-1 had only a modest effect. Ultrastructural analysis revealed marked cytoplasmic vacuolization following SR-BI inhibition. These findings indicate that altered cholesterol metabolism is closely associated with cytoplasmic vacuolization in MM cells, suggesting that SR-BI plays a critical role in MM cell survival. Therefore, targeting the cholesterol trafficking pathways may represent a potential therapeutic strategy in MM.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
- Department of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-Ku, Kumamoto, 862-0976, Japan. yano-h@kumamoto-u.ac.jp.
- Department of Pathology, Faculty of Medicine, Shimane University, 89-1, Enyamachi, Izumo-Shi, Shimane, 693-8501, Japan.
- Department of Hematology, Rheumatology, and Infectious Disease, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
- Department of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-Ku, Kumamoto, 862-0976, Japan.
- Center for Metabolic Regulation of Healthy Aging, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Förderung
- Kumamoto University
Zitieren
APA
Kondo, Y., Yano, H., Fujiwara, Y., Niino, D., Kawano, Y., Yasunaga, J. I., Yamamoto, M., & Komohara, Y. (2026). Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma. Medical Molecular Morphology. https://doi.org/10.1007/s00795-026-00466-2
Vancouver
Kondo Y, Yano H, Fujiwara Y, Niino D, Kawano Y, Yasunaga JI, et al. Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma. Medical Molecular Morphology. 2026. doi:10.1007/s00795-026-00466-2
BibTeX
@article{Kondo2026,
author = {Kondo, Yoshihiko and Yano, Hiromu and Fujiwara, Yukio and Niino, Daisuke and Kawano, Yawara and Yasunaga, Jun-Ichirou and Yamamoto, Masahiro and Komohara, Yoshihiro},
title = {Scavenger receptor class B type I (SR-BI) as a potential therapeutic target in multiple myeloma},
journal = {Medical Molecular Morphology},
year = {2026},
doi = {10.1007/s00795-026-00466-2}
}
EUVIMED